EIGR

Eiger BioPharmaceuticals Inc

Healthcare


Presented:03/06/2019
Price:$13.48
Cap:$0.26B
Current Price:$8.50
Cap:$0.01B

Presented

Date03/06/2019
Price$13.48
Market Cap$0.26B
Ent Value$0.13B
P/E RatioN/A
Book Value$1.77
Div Yield0%
Shares O/S19.10M
Ave Daily Vol134,508
Short Int1.82%

Current

Price$8.50
Market Cap$0.01B
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for orphan diseases. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.

Publicly traded companies mentioned herein: Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD)

Highlights

The presenter is long shares of Eiger Biopharmaceuticals (EIGR) at ~$14 due to his belief that its underlying revenue and pipeline opportunities are underappreciated by the market. With Lonafarnib + Ritonavir in Phase 3 for hepatitis delta virus (HDV), and good data thus far, it could be the first FDA-approved treatment for a relatively large orphan population. HDV is the most severe form of viral hepatitis in humans, affecting ~6% of the Hepatitis B population. Additionally, EIGR is preparing the NDA for Lonafarnib in Hutchinson-Gilford Progeria Syndrome (Progeria), an extremely rare, autosomal dominant, fatal, premature aging syndrome. He added that the expanded access program has already been set up, as the ~140 global patient population is known. With a market cap of just ~$250MM and the potential for >$1B in Lonafarnib sales, the risk/reward setup is very attractive.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.